Pravastatin Sodium Articles
Pharma DTC web sites failing to address consumer needs, says study
14 September 2001
Analysts comment on Crestor safety data
14 September 2001
Stock Commentary - New York
13 September 2001
Crestor "as safe as other statins"
13 September 2001
Bristol-Myers Squibb in Florida Medicaid deal
10 September 2001
Stock Commentary - Tokyo
6 September 2001
Japan pharma stocks, week to Sept 3rd
5 September 2001
New data supports Pravachol safety
4 September 2001
Will Pfizer/Florida deal be the first of many?
10 July 2001
B-MS 1st-qtr pharma sales up 8% at $3.7B
26 April 2001
Pravastatin action on CRP a class effect?
17 April 2001
Tokyo pharma stock market - week to March 26, 2001
27 March 2001
B-MS cuts heart disease risk factor
22 March 2001
Stock Commentary - Tokyo
8 March 2001
Tokyo stock watch, week to March 5
7 March 2001
Pravastatin cuts diabetes risk; WOSCOPS data
25 January 2001
Bristol-Myers Squibb's "solid year" sees net earnings rise 13%
25 January 2001
Stroke prevention emerges from heart disease
10 January 2001
Antithrombotic delay mars upbeat AstraZeneca R&D meeting
13 December 2000
Stock Commentary - Tokyo
26 October 2000
B-MS net earnings increase 13%
23 October 2000
B-MS focuses on intense growth and reveals product pipeline
2 October 2000
B-MS "may sue" Canada over patents
28 September 2000
New data dispute extreme lipid-lowering
6 September 2000
Pravastatin shows effect in reducing stroke
1 August 2000
B-MS up on strong sales of Glucophage
24 July 2000
FDA says Mevacor should not go OTC, at least for now
14 July 2000
Media criticized over new drug reporting
5 June 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
B-MS and W-L go head-to-head with statins
10 November 1999
World's top-selling drugs; 2002 forecasts
13 August 1999
Pravastatin shown to be anti-inflammatory
20 July 1999
US DTC Rx ad spend hit $1.3 billion in 1998
25 May 1999
Pharmacoeconomics: Canada's "Template?"
28 October 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
W-L's Lipitor "Will Be World Top-Seller In 2005"
3 August 1998
US Rx DTC Ad Spend Set To Beat $1 Billion Again
28 July 1998
B-MS Injunction Fails In Canadian Court
16 June 1998
New Labeling For Pravachol
15 June 1998
US Quarterly Financial Results Round-Up
23 April 1998
FDA OKs Two Statins For Stroke Prevention
2 April 1998
Baycol Launched In Third Major Market
19 February 1998
Greece To Slim Official Drug List
4 February 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Predicting Responders To Statin Therapy
8 January 1998
Australia Excludes SSRIs From Final TGP Scheme
17 December 1997
Drug Promo Meetings "Up 61% Since 1995"
27 October 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
US DTC Advertising Is Fastest Growing Promotional Segment
21 October 1997
Greek Govt Adjusts Prices Of 6,009 Drugs
3 October 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
B-MS In Czech Republic
30 May 1997
"Solid Growth" At Bristol-Myers Squibb
5 May 1997
Lipitor To Drive Outperformance At W-L?
14 March 1997
US Rx Drug Sales For 1996 Up 10% At $85.35 Billion
24 February 1997
First Launch Of Parke-Davis' Lipitor
10 February 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Atorvastatin: 1st Approvals In UK And Germany
9 December 1996
New Statin Data Should Benefit Female Patients
25 November 1996
Major US Drug Cos Post Strong Results In 3rd Qtr
28 October 1996
Sales Team Expands At Bristol-Myers Squibb
16 September 1996
FDA Clears Pravachol For First Heart Attack
22 July 1996
Volume Growth Boosts B-MS' First Quarter
6 May 1996
US Approval For B-MS' Heart Drug Pravachol
22 April 1996
Pipeline Contains Two Blockbusters, Says W-L
22 April 1996
11% 1st-Qtr EPS Rise From US Drug Cos
15 April 1996
Losec "Will Be The World's Top-Selling Drug In 2000"
26 February 1996
Mixed Results For Q4 1995 From US Drug Majors
29 January 1996
cholesterol-lowering agents implicated as carcinogens
15 January 1996
Pravastatin Prevents First Heart Attack; WOS Study
27 November 1995
US FTC "Must Monitor Company/PBM Deals"
20 November 1995
Greek Drug Prices "Much Higher Than EU Average"
13 November 1995
Bristol-Myers research operations
31 July 1995
Disease ManagementThe Way Forward
15 May 1995
Pravachol Label Change Reveals MI Benefit
24 April 1995
Pravachol Slows Coronary Atherosclerosis
3 April 1995
January Rx Trends In The USA
13 March 1995
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
